



**Supplementary Figure 9.** Comparison of adverse events between 10-/14-day bismuth quadruple therapy and other regimens (standard triple therapy, sequential therapy, concomitant therapy). Risk of bias: A, random sequence generation (selection bias); B, allocation concealment (selection bias); C, blinding of participants and personnel (performance bias); D, blinding of outcome assessment (detection bias); E, incomplete outcome data (attrition bias); F, selective reporting (reporting bias); G, other bias. PBMT, bismuth quadruple therapy; M-H, Mantel-Haenszel; CI, confidence interval.